Acquisition deepens AbbVie’s robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases Apogee’s lead asset, zumilokibart,…
AbbVie Completes Acquisition of Apogee Therapeutics
calendar_today
September 3, 2026
domain
abbvie